Lilly and Novo whipsaw Wall Street with split in obesity outlook

2026-02-04 - 21:55

Within the span of 19 hours, weight loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. offered wildly divergent views on where business is headed. After Novo shocked the market by warning sales could decline by as much as 13 per cent this year, Lilly followed with a surprise to the upside, forecasting an as much as 27 per cent rise. Read More